SEABREEZE STAT COPD - Clinical Trial
¿Cuál es el Propósito de este estudio?
If you join this study, you will first go through a screening period to make sure you qualify. If you qualify, you will be placed into one of two groups by chance, like drawing names from a hat. Group 1 will get one dose of a medicine called rademikibart. Group 2 will get one dose of a placebo, which looks like the medicine but does not have any active drug. The study will include about nine visits over a period of eight to thirty-four weeks.
Chronic Obstructive Pulmonary Disease (COPD)
¿Quién puede participar en el Estudio?
People can join this study if they are between 40 and 80 years old and have had COPD for at least one year. They must have had at least one COPD flare-up in the past year. They must be current or former smokers. They also cannot have asthma right now.
¿Qué Implica?
This study wants to learn if people who have COPD and Type 2 inflammation get better after a COPD flare‑up when they take a new medicine called rademikibart along with the regular COPD treatments their doctor already gives them.
Detalles del Estudio
